Calls to action at #NYLCF23 : Dr. Luis Paz-Ares asks when can we remove central labs from clinical trials? We need to remove archaic overinterpretation of GCP like signing all labs and creating so many CRFs. New York Lung Cancer Foundation
Setting priorities for the next two years!
Cooperation, enthusiasm and above all optimism!
#NYLCF23 #lungcancer New York Lung Cancer Foundation
Very Interesting discussion on Immunotherapy 🫁in Lung Cancer and a “call to action” to “personalize” IO, improving biomarker research. #NYLCF23 Fred R. Hirsch Fabrice Barlesi Daniel Tan Solange Peters Dr. Katerina Politi Hossein Borghaei, DO Vamsi Velcheti, MD MBA OncoAlert
Insightful panel on diversity & disparities. Dr. Raymond Osarogiagbon, MBBS, FACP explains “you cannot change what you do not measure.” Dr. Enriqueta Felip highlights differences in access across Europe. Dr. Sukhmani (Suki) Padda MD - we must address the lack of diversity in the oncology workforce. #NYLCF23
Forward facing #SCLC session at #NYLCF23 brainstorming strategies to leverage subtyping efforts and deliver newer agents including ADCs and BiTEs. Charlie Rudin Federico Cappuzzo Jacob sands Deborah Doroshow Triparna Sen (Sen-Lab) New York Lung Cancer Foundation
Panel on implementation of new drugs highlights some of the limitations of real world data and the need for pragmatic trials to fill in the gaps. Harpreet Singh, MD Tony Mok LUNGevity Foundation New York Lung Cancer Foundation #NYLCF23
Discussion on new technologies and lung cancer has to include equitable and universal access to these new technologies #NYLCF23 chadi nabhan MD, MBA, FACP Geoff Oxnard MD Max Diehn, MD/PhD New York Lung Cancer Foundation
#NYLCF23 its just starting with a exciting agenda and faculty! Thanks to the chairs Fred R. Hirsch Solange Peters Tony Mok for the invitation to discuss about #liquidbiopsy in lung cancer screening 🫁 🩸🩻with Claudia Henschke Anne-Marie Dingemans prof. Ola Khorshid International Society of Liquid Biopsy
Important theme at #NYLCF23 is collaboration. Panel here discussing relationships between academia, industry, and organizations like LUNGevity Foundation IASLC. New York Lung Cancer Foundation
Successful partnership between academia, industry and organizations.
And the example of Lung-MAP . An important session session and great insights. Karen Kelly Everett Vokes Dr. Bruce Johnson at #NYLCF23 🗽 Fred R. Hirsch Tony Mok Solange Peters
Outstanding insights on new technology in lung cancer 🫁 from NGS in tissue to #liquidbiopsy to the use of AI in pathology by Max Diehn, MD/PhD Geoff Oxnard MD S. Dacic , Phil Mack at #NYLCF23
Dr Ned Sharpless Norman Sharpless former National Cancer Institute Director ready to give the Keynote lecture at #NYLCF23 meeting on “Perspectives on Future Cancer Therapy”. Fred R. Hirsch Solange Peters Tony Mok OncoAlert
Fantastic panel discussing early stage NSCLC needs and future clinical trials. A lot to discuss and do to improve this therapeutic landscape. Heather Wakelee Roy Herbst David Carbone MD nasser altorki raja flores Brendon Stiles LudaBazhenovaMD Jamie Chaft at #NYLCF23 New York 🗽
#NYLCF23 panel on new technology with an exciting discussion about the future roles of liquid biopsy, NGS, and artificial and digital pathology with Drs. Max Diehn, MD/PhD Geoff Oxnard MD and Sanja Dacic. New York Lung Cancer Foundation
Dr. Christian Rolfo with a call for creative and pragmatic correlative studies New York Lung Cancer Foundation #NYLCF23 Fred R. Hirsch
Interesting SCLC session at #NYLCF23 very interesting discussions on molecular classification and correlation with IO sensitivity or resistance. Triparna Sen (Sen-Lab) Charlie Rudin Federico Cappuzzo Deborah Doroshow
Engaging discussion chaired by Drs. Bruce Johnson and Everett Vokes. Need to work with industry, CROs, and regulatory authorities to streamline data collection and make trials easier to run. #NYLCF23 New York Lung Cancer Foundation
